The guidelines that now exist are very weak and operate at the margins. They lack monitoring, and, for the most part, they lack teeth.
The more lucrative the drug market, the higher the percentage of experts with financial ties - that has to raise serious questions about these panels' objectivity.
Drug companies spend $13,000 per physician annually. Those marketing tactics are very, very effective at getting physicians to do what each drug company wants -- to prescribe their product.